Piyasa kapalı· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
SAN ANTONIO, September 30, 2026--bioAffinity and AvMEDICAL jointly presented CyPath Lung for the first time under their new distribution agreement at NAVREF 2026 Annual Conference.
bioAffinity Technologies (NASDAQ:BIAF) is continuing to build momentum behind its non-invasive lung cancer diagnostic, CyPath Lung, with new clinical evidence and an expanding route into the US federal healthcare market. The company is presenting real-world clinical cases and new research focused on veteran and military populations at the 2026 NAVREF Annual Conference, highlighting the potential role of CyPath Lung in helping physicians make more informed diagnostic decisions.
bioAffinity Technologies (NASDAQ:BIAF) will present new clinical findings on its noninvasive lung cancer test, CyPath® Lung, at the 2026 NAVREF Annual Conference, running September 27–30 in Arlington, Virginia. The company is set to unveil two posters focused on the test’s use in veteran and military healthcare settings.
SAN ANTONIO, September 22, 2026--bioAffinity Technologies will present two posters related to the CyPath Lung diagnostic test for lung cancer at the 2026 NAVREF Annual Conference.
The new patent extends intellectual property protection for the company’s noninvasive lung cancer detection technology in Asia, complementing its existing Chinese patent. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) has received a Hong Kong patent covering core technology used in its CyPath Lung diagnostic test.
SAN ANTONIO, September 17, 2026--bioAffinity announces new Hong Kong patent that protects the proprietary technology behind its noninvasive CyPath Lung diagnostic for lung cancer.
SAN ANTONIO, September 09, 2026--bioAffinity Technologies received notice that it has regained compliance with Nasdaq's applicable listing requirements.
bioAffinity Technologies jumped 47.95% on September 2, one day after announcing that it was advancing the potential use of CyPath Lung for post-treatment surveillance of lung-cancer patients. The move followed a 1-for-15 reverse split that became effective for trading on August 24, a combination that can produce dramatic percentage swings in a thinly traded stock. […]
SAN ANTONIO, September 03, 2026--BIAF President and CEO Maria Zannes will present a corporate update at the H.C. Wainwright 28th Annual Global Investment Conference Sept. 14-16.
bioAffinity Technologies (NASDAQ:BIAF) shares rose 39. 4% in premarket trading after the company announced that its CyPath® Lung noninvasive diagnostic test is now positioned for post-curative surveillance of lung cancer recurrence.
The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor TakeawaysbioAffinity Technologies (NASDAQ:BIAF) is advancing CyPath Lung for potential use in post-treatment lung cancer surveillance, expanding its focus beyond early detection.
SAN ANTONIO, September 01, 2026--bioAffinity Technologies is advancing the application of its CyPath Lung test for surveillance of lung cancer patients who have completed treatment.
SAN ANTONIO, August 20, 2026--bioAffinity Technologies will effect a 1-for-15 reverse split of its common stock at the opening of trading on Nasdaq on August 24, 2026.
bioAffinity Technologies, Inc. (NASDAQ:BIAF) has signed a nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung, giving the lung cancer diagnostic access to an established government sales and procurement network.
SAN ANTONIO, August 18, 2026--bioAffinity Technologies enters distribution agreement with AvMEDICAL to expand CyPath Lung sales reach and access to government healthcare systems.
WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 shares of common stock. The combined e
SAN ANTONIO, August 14, 2026--bioAffinity Technologies announces closing of $4M private placement offering.
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.